The Manila Times

Johnson & Johnson receives European Commission approval of IMAAVY® (nipocalimab), a new ...

Nipocalimab is the first FcRn blocker approved in both adult and adolescent gMG patients aged 12 and older who are anti-AChR or anti-MuSK antibody-positive ...